Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints

• Drug: PF-05089771 300mg
  
  PF-05089771 300 mg
• Drug: PF-05089771 300 mg + pregabalin 300 mg
  
  PF-05089771 300 mg + pregabalin 300 mg
• Drug: Placebo
  
  Placeco
• Drug: pregabalin 300 mg
  
  pregabalin 300 mg
• Drug: ibuprofen 600 mg
  
  ibuprofen 600 mg

• Experimental: PF-05089771 300 mg
  
  Intervention: Drug: PF-05089771 300mg
• Experimental: PF-05089771 300 mg + pregabalin 300 mg
  
  Intervention: Drug: PF-05089771 300 mg + pregabalin 300 mg
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo
• Active Comparator: pregabalin 300 mg
  
  Intervention: Drug: pregabalin 300 mg
• Active Comparator: ibuprofen 600 mg
  
  Intervention: Drug: ibuprofen 600 mg

Inclusion Criteria:

• Healthy male subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests. ?Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs). ?Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. ?Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). ?Any condition possibly affecting drug absorption (eg, gastrectomy). ?A positive urine drug screen